1) Background: Rapid and acurate diagnostic testing for case identification, quarantine, and contact tracing is essential for managing the COVID 19 pandemic. Rapid antigen detection tests are available, however, it is...1) Background: Rapid and acurate diagnostic testing for case identification, quarantine, and contact tracing is essential for managing the COVID 19 pandemic. Rapid antigen detection tests are available, however, it is important to evaluate their performances before use. We tested a rapid antigen detection of SARS-CoV-2, based on the immunochromatography (Boson Biotech SARS-CoV-2 Ag Test (Xiamen Boson Biotech Co., Ltd., China)) and the results were compared with the real time reverse transcriptase-Polymerase chain reaction (RT-PCR) (Gold standard) results;2) Methods: From November 2021 to December 2021, samples were collected from symptomatic patients and asymptomatic individuals referred for testing in a hospital during the second pandemic wave in Gabon. All these participants attending “CTA Angondjé”, a field hospital set up as part of the management of COVID-19 in Gabon. Two nasopharyngeal swabs were collected in all the patients, one for Ag test and the other for RT-PCR;3) Results: A total of 300 samples were collected from 189 symptomatic and 111 asymptomatic individuals. The sensitivity and specificity of the antigen test were 82.5% [95%CI 73.8 - 89.3] and 97.9 % [95%CI 92.2 - 98.2] respectively, and the diagnostic accuracy was 84.4% (95% CI: 79.8 - 88.3%). The antigen test was more likely to be positive for samples with RT-PCR Ct values ≤ 32, with a sensitivity of 89.8%;4) Conclusions: The Boson Biotech SARS-CoV-2 Ag Test has good sensitivity and can detect SARS-CoV-2 infection, especially among symptomatic individuals with low viral load. This test could be incorporated into efficient testing algorithms as an alternative to PCR to decrease diagnostic delays and curb viral transmission.展开更多
Objective:To explore potential inhibitors of viral enzymes of SARS CoV-2.Methods:The in-silico docked potential of anti-viral,antibiotic,and analgesic drugs were studied for inhibition of the nonstructural protein(NSP...Objective:To explore potential inhibitors of viral enzymes of SARS CoV-2.Methods:The in-silico docked potential of anti-viral,antibiotic,and analgesic drugs were studied for inhibition of the nonstructural protein(NSP)9,NSP3,and NSP15 of SARS CoV-2 using recent structural peculiarities of these enzymes,3 D optimized structures of drugs and algorithm-based ligand inhibitory potential.Results:Teicoplanin,azithromycin,and remdesivir potentially inhibited NSP9(Dock-score 9620,5472 and 6252,respectively),NSP3(Dock-score 9846,5604 and 5548,respectively)and NSP15(Dock-score 10960,6414 and 6002,respectively).Conclusions:Teicoplanin acts as a significant receptor antagonist and potentially inhibits the SARS CoV-2 enzymes.展开更多
Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been a global threat spreading in Sierra Leone, and many studies are being conducted using various Statistical models to predict the probable evolution ...Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been a global threat spreading in Sierra Leone, and many studies are being conducted using various Statistical models to predict the probable evolution of this pandemic. In this paper, we use the autoregressive integrated moving average (ARIMA) model with the aim of forecasting the cumulative confirmed cases of SARS CoV-2 in Sierra Leone. The Akaike Information Criterion (AIC) was applied to the training data as a criterion method to select the best model. In addition, the statistical measure RMSE and MAPE were utilized for testing this data, and the model with the minimum RMSE and MAPE was selected for future forecasting. ARIMA (3, 2, 1) was confirmed to be the optimal model based on the lowest AIC value. This model was then applied to study the trend of SARS CoV-2 from 1st February 2022 to 30th February 2022. The result shows that incidence of SARS CoV-2 from 1st February 2022 to 30th February 2022, increasing growth steep in Sierra Leone (7718.629, 95% confidence limit of 6785.985 - 8651.274).展开更多
There have been reported a large number of neurological symptoms in CoV-2 infected patients after the COVID-19 outbr<span style="font-family:Verdana;font-size:12px;">eak</span><span style=&quo...There have been reported a large number of neurological symptoms in CoV-2 infected patients after the COVID-19 outbr<span style="font-family:Verdana;font-size:12px;">eak</span><span style="font-family:Verdana;font-size:12px;"> was declared in January 2020. Cases reports as well as series of COVID-19 patients have shown a wide variety of neurological symptoms such as stroke, encephalomyelitis, polyradiculoneuropathy and other neurological conditions. Despite the fact, a high </span><span style="font-family:Verdana;font-size:12px;">incidence of neurological symptoms have been reported during the</span><span style="font-family:Verdana;font-size:12px;"> COVID-19 pandemic, the proportion of them in acute and in a more chronic phase has not been exactly described in most of the papers published until now. We described in this article the neurological symptoms in a series of COVID-19 patients during the acute phase of infection while they were admitted into the hospital and subsequently the persisting neurological symptoms showed in the following 6</span><span style="font-family:Verdana;font-size:12px;"> </span><span style="font-family:Verdana;font-size:12px;">months in the outpatients’ evaluation once they were discharged from the hospital in the province of Catalonia-Spain from January to June of 2020</span><span style="font-family:Verdana;font-size:12px;">.</span>展开更多
目的系统评价糖尿病患者在接种SARS-CoV-2疫苗后的体液和细胞免疫反应。方法检索Web of Science、PubMed、中国知网、万方数据知识服务平台、维普中文科技期刊全文数据库和中国生物医学文献数据库,获取国内外于2019年12月1日至2022年5...目的系统评价糖尿病患者在接种SARS-CoV-2疫苗后的体液和细胞免疫反应。方法检索Web of Science、PubMed、中国知网、万方数据知识服务平台、维普中文科技期刊全文数据库和中国生物医学文献数据库,获取国内外于2019年12月1日至2022年5月12日公开发表的有关糖尿病患者接种SARS-CoV-2疫苗后的体液和细胞免疫反应的观察性研究,经由2名研究者独立筛选文献和提取资料后,采用美国国立卫生研究质量评价工具对纳入文献进行偏倚风险评价,使用描述性统计方法进行汇总分析。结果13篇文献共纳入66651例研究对象,其中5874例(7.9%)患有糖尿病。7篇文献报道了接种第1剂疫苗后糖尿病患者和对照组的免疫反应,其中3篇文献表明,接种1剂SARS-CoV-2疫苗后,糖尿病患者血清抗体水平和阳性率低于对照组;11篇涉及接种2剂SARS-CoV-2疫苗后的免疫反应的文献中,2篇报道了糖尿病患者可产生与对照组相似的抗体反应,9篇报道了糖尿病患者的血清抗体水平、阳性率或细胞免疫反应低于对照组。结论接种SARS-CoV-2疫苗后糖尿病患者和对照组体液和细胞免疫反应均有所增加,但糖尿病患者增加幅度普遍低于对照组。展开更多
文摘1) Background: Rapid and acurate diagnostic testing for case identification, quarantine, and contact tracing is essential for managing the COVID 19 pandemic. Rapid antigen detection tests are available, however, it is important to evaluate their performances before use. We tested a rapid antigen detection of SARS-CoV-2, based on the immunochromatography (Boson Biotech SARS-CoV-2 Ag Test (Xiamen Boson Biotech Co., Ltd., China)) and the results were compared with the real time reverse transcriptase-Polymerase chain reaction (RT-PCR) (Gold standard) results;2) Methods: From November 2021 to December 2021, samples were collected from symptomatic patients and asymptomatic individuals referred for testing in a hospital during the second pandemic wave in Gabon. All these participants attending “CTA Angondjé”, a field hospital set up as part of the management of COVID-19 in Gabon. Two nasopharyngeal swabs were collected in all the patients, one for Ag test and the other for RT-PCR;3) Results: A total of 300 samples were collected from 189 symptomatic and 111 asymptomatic individuals. The sensitivity and specificity of the antigen test were 82.5% [95%CI 73.8 - 89.3] and 97.9 % [95%CI 92.2 - 98.2] respectively, and the diagnostic accuracy was 84.4% (95% CI: 79.8 - 88.3%). The antigen test was more likely to be positive for samples with RT-PCR Ct values ≤ 32, with a sensitivity of 89.8%;4) Conclusions: The Boson Biotech SARS-CoV-2 Ag Test has good sensitivity and can detect SARS-CoV-2 infection, especially among symptomatic individuals with low viral load. This test could be incorporated into efficient testing algorithms as an alternative to PCR to decrease diagnostic delays and curb viral transmission.
基金supported by Institute of Chemistry,University of the Punjab Lahore,Pakistan
文摘Objective:To explore potential inhibitors of viral enzymes of SARS CoV-2.Methods:The in-silico docked potential of anti-viral,antibiotic,and analgesic drugs were studied for inhibition of the nonstructural protein(NSP)9,NSP3,and NSP15 of SARS CoV-2 using recent structural peculiarities of these enzymes,3 D optimized structures of drugs and algorithm-based ligand inhibitory potential.Results:Teicoplanin,azithromycin,and remdesivir potentially inhibited NSP9(Dock-score 9620,5472 and 6252,respectively),NSP3(Dock-score 9846,5604 and 5548,respectively)and NSP15(Dock-score 10960,6414 and 6002,respectively).Conclusions:Teicoplanin acts as a significant receptor antagonist and potentially inhibits the SARS CoV-2 enzymes.
文摘Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been a global threat spreading in Sierra Leone, and many studies are being conducted using various Statistical models to predict the probable evolution of this pandemic. In this paper, we use the autoregressive integrated moving average (ARIMA) model with the aim of forecasting the cumulative confirmed cases of SARS CoV-2 in Sierra Leone. The Akaike Information Criterion (AIC) was applied to the training data as a criterion method to select the best model. In addition, the statistical measure RMSE and MAPE were utilized for testing this data, and the model with the minimum RMSE and MAPE was selected for future forecasting. ARIMA (3, 2, 1) was confirmed to be the optimal model based on the lowest AIC value. This model was then applied to study the trend of SARS CoV-2 from 1st February 2022 to 30th February 2022. The result shows that incidence of SARS CoV-2 from 1st February 2022 to 30th February 2022, increasing growth steep in Sierra Leone (7718.629, 95% confidence limit of 6785.985 - 8651.274).
文摘There have been reported a large number of neurological symptoms in CoV-2 infected patients after the COVID-19 outbr<span style="font-family:Verdana;font-size:12px;">eak</span><span style="font-family:Verdana;font-size:12px;"> was declared in January 2020. Cases reports as well as series of COVID-19 patients have shown a wide variety of neurological symptoms such as stroke, encephalomyelitis, polyradiculoneuropathy and other neurological conditions. Despite the fact, a high </span><span style="font-family:Verdana;font-size:12px;">incidence of neurological symptoms have been reported during the</span><span style="font-family:Verdana;font-size:12px;"> COVID-19 pandemic, the proportion of them in acute and in a more chronic phase has not been exactly described in most of the papers published until now. We described in this article the neurological symptoms in a series of COVID-19 patients during the acute phase of infection while they were admitted into the hospital and subsequently the persisting neurological symptoms showed in the following 6</span><span style="font-family:Verdana;font-size:12px;"> </span><span style="font-family:Verdana;font-size:12px;">months in the outpatients’ evaluation once they were discharged from the hospital in the province of Catalonia-Spain from January to June of 2020</span><span style="font-family:Verdana;font-size:12px;">.</span>
文摘目的系统评价糖尿病患者在接种SARS-CoV-2疫苗后的体液和细胞免疫反应。方法检索Web of Science、PubMed、中国知网、万方数据知识服务平台、维普中文科技期刊全文数据库和中国生物医学文献数据库,获取国内外于2019年12月1日至2022年5月12日公开发表的有关糖尿病患者接种SARS-CoV-2疫苗后的体液和细胞免疫反应的观察性研究,经由2名研究者独立筛选文献和提取资料后,采用美国国立卫生研究质量评价工具对纳入文献进行偏倚风险评价,使用描述性统计方法进行汇总分析。结果13篇文献共纳入66651例研究对象,其中5874例(7.9%)患有糖尿病。7篇文献报道了接种第1剂疫苗后糖尿病患者和对照组的免疫反应,其中3篇文献表明,接种1剂SARS-CoV-2疫苗后,糖尿病患者血清抗体水平和阳性率低于对照组;11篇涉及接种2剂SARS-CoV-2疫苗后的免疫反应的文献中,2篇报道了糖尿病患者可产生与对照组相似的抗体反应,9篇报道了糖尿病患者的血清抗体水平、阳性率或细胞免疫反应低于对照组。结论接种SARS-CoV-2疫苗后糖尿病患者和对照组体液和细胞免疫反应均有所增加,但糖尿病患者增加幅度普遍低于对照组。
